ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1519

Interleukin-17D, a Cytokine Derived from Stromal Cells, Attenuates Joint Inflammation

Sijia Chen1, Catherine Manning2, Melissa van Tok3, Yukiko Maeda4, Daniel Montoro5, Jung-Min Kim6, Jeroen den Dunnen3, Nataliya Yeremenko3, Jae-Hyuck Shim4, Dominique Baeten7 and Ellen Gravallese8, 1Brigham and Women's Hospital, Boston, 2Brigham and Women’s Hospital, Boston, 3Amsterdam University Medical Centers, Amsterdam, Netherlands, 4University of Massachusetts Medical School, worcester, MA, 5Broad Institute of Massachusetts Institute of Technology and Harvard, Boston, 6University of Massachusetts Medical School, Worcester, 7UCB Pharma / Amsterdam University Medical Centers, Amsterdam, Netherlands, 8Brigham and Women's Hospital, Boston, MA

Meeting: ACR Convergence 2020

Keywords: Animal Model, Fibroblasts, Synovial, Inflammation, Interleukins, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1517–1521)

Session Type: Abstract Session

Session Time: 5:00PM-5:50PM

Background/Purpose: Interleukin(IL)-17D is a little recognized member of the IL-17 family of cytokines. While the activities of IL-17A and IL-17F in the pathogenesis of spondyloarthritis (SpA) are established, a role for IL-17D in SpA and tissue inflammation has not yet been demonstrated.

Methods: In order to identify the cell types that express IL-17D in SpA synovial tissue and in primary human cells, we performed RNA sequencing, qPCR and IF analyses. We isolated fibroblast-like synoviocytes (FLS) from inflamed SpA synovial tissues, and stimulated cultured FLS with cytokines or subjected FLS to osteogenic differentiation. To determine a potential role for IL-17D in bone, femurs from il17d-/- mice were assessed by micro-computed tomography analysis. Serum transfer arthritis (STA) was also induced in il17d-/- mice and we performed subsequent Luminex assays to assess circulating cytokine expression at peak inflammation.

Results: In SpA inflamed synovial tissues, we demonstrate that IL-17D mRNA is more highly expressed than any other IL-17 family member, and that IL-17D is expressed by FLS that stain positive for markers of multipotent mesenchymal stromal cells (MSCs). In vitro, FLS express IL-17D at baseline. Osteogenic differentiation upregulates IL-17D mRNA in FLS when differentiated to osteoblast-like cells. In vivo, cells with the morphologic appearance of osteoblasts in bone sections also express IL-17D. However, Il17d-/- mice fail to demonstrate a bone phenotype, suggesting that IL-17D deletion does not impact bone homeostasis. Importantly, there is an inverse correlation between IL-17D expression and inflammation in vitro and in vivo. Anti-IL-17A treatment in SpA patients decreases synovial inflammation, and correlates with an increase in synovial IL-17D mRNA expression. Additionally, Il17d-/- mice demonstrate a more severe arthritis than littermate controls, and show elevated levels of pro-inflammatory cytokines at peak inflammation in STA, including TNFα, MCP-1 and MIP-1α.

Conclusion: These data demonstrate that IL-17D is the most highly-expressed IL-17 family member in inflamed SpA synovium. We localized IL-17D expression to stromal cells, including FLS. Furthermore, IL-17D expression is downregulated during human and experimental SpA inflammation, and evidence from STA indicates that this cytokine may exert an anti-inflammatory effect on joint inflammation.


Disclosure: S. Chen, None; C. Manning, None; M. van Tok, Merck KGaA, 3; Y. Maeda, None; D. Montoro, None; J. Kim, None; J. den Dunnen, None; N. Yeremenko, None; J. Shim, None; D. Baeten, UCB pharma, 3; E. Gravallese, New England Journal of Medicine, 3, UpToDate, 7, Co-editor of the textbook Rheumatology, 7.

To cite this abstract in AMA style:

Chen S, Manning C, van Tok M, Maeda Y, Montoro D, Kim J, den Dunnen J, Yeremenko N, Shim J, Baeten D, Gravallese E. Interleukin-17D, a Cytokine Derived from Stromal Cells, Attenuates Joint Inflammation [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/interleukin-17d-a-cytokine-derived-from-stromal-cells-attenuates-joint-inflammation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interleukin-17d-a-cytokine-derived-from-stromal-cells-attenuates-joint-inflammation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology